Drug Trial Radar · NCT07631884
Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
May 12, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2028
Sponsor
- Lead sponsor
- Haihua YuanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 8, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if Trastuzumab Rezetecan can treat advanced solid tumors with HER-2 expression in adult participants. The main question it aims to answer is: What is the objective response rate of Trastuzumab Rezetecan in adult patients with HER-2 expressed advanced solid tumors? Participants will receive intravenous infusion of Trastuzumab Rezetecan on Day 1 of each 21-day treatment cycle. The dosage is 4.8 mg/kg per cycle; participants with a body weight of 85 kg or above will receive a fixed dose of 408 mg every 3 weeks.
Conditions
- Solid Tumors
- Neoplasms (Cancer / Tumors)
- Advanced Malignant Solid Neoplasm
- Locally Advanced Malignant Solid Neoplasm
- Unresectable Malignant Solid Neoplasm
- Metastatic Malignant Solid Neoplasm
- HER2 Expression
- Biliary Tract Neoplasms
- Endometrial Neoplasms
- Urothelial Carcinoma (UC)
- Pancreatic Neoplasms
- Colorectal Neoplasms
- Gastric Neoplasms
- Non-Small Cell Lung Carcinoma (NSCLC)
- Head and Neck Neoplasms
- Cervical Neoplasms
Interventions
Trastuzumab RezetecanDrug
Trastuzumab Rezetecan will be administered on Day 1 of each 21-day cycle as specified. The dose is 4.8 mg/kg (fixed 408 mg for body weight ≥85 kg). Treatment continues until tumor progression or occurrence of unacceptable toxicity.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate, ORRTime frame: From the date of first study treatment until disease progression or death from any cause, whichever occurs first, assessed up to 24months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Shanghai, Shanghai Municipality, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.